Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Significant Drop in Short Interest

Azitra, Inc. (NYSEAMERICAN:AZTR) was the target of a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 154,671 shares, a drop of 55.8% from the July 15th total of 349,646 shares. Based on an average trading volume of 769,462 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.0% of the company’s shares are short sold.

Azitra Trading Down 0.5%

Shares of AZTR stock traded down $0.00 on Friday, hitting $0.14. 1,041,981 shares of the stock traded hands, compared to its average volume of 1,476,759. The firm’s 50-day moving average price is $0.16 and its two-hundred day moving average price is $0.19. Azitra has a twelve month low of $0.10 and a twelve month high of $1.40.

Azitra (NYSEAMERICAN:AZTR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). As a group, equities analysts predict that Azitra will post -0.25 earnings per share for the current year.

About Azitra

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.